Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION (Details) - Segments Information

v3.19.3.a.u2
SEGMENT INFORMATION (Details) - Segments Information - USD ($)
12 Months Ended
Oct. 31, 2019
Oct. 31, 2018
Net loss:    
Net Loss $ (11,818,652) $ (14,243,084)
Total operating costs and expenses 12,140,005 15,401,558
Less non-cash share-based compensation (5,713,746) (8,895,614)
Operating costs and expenses excluding non-cash share-based compensation 6,426,259 6,505,944
Operating costs and expenses excluding non-cash share based compensation expense:    
Operating costs and expenses excluding non-cash share-based compensation 6,426,259 6,505,944
Total assets:    
Total Assets 6,293,693 6,448,542
Operating Segments [Member] | Cancer Diagnostics [Member]    
Net loss:    
Net Loss (5,196,471) (5,920,457)
Operating costs and expenses excluding non-cash share-based compensation 2,689,761 2,431,810
Operating costs and expenses excluding non-cash share based compensation expense:    
Operating costs and expenses excluding non-cash share-based compensation 2,689,761 2,431,810
Total assets:    
Total Assets 2,921,784 2,545,803
Operating Segments [Member] | Cancer Therapeutics [Member]    
Net loss:    
Net Loss (5,752,318) (7,073,322)
Operating costs and expenses excluding non-cash share-based compensation 2,670,482 2,120,614
Operating costs and expenses excluding non-cash share based compensation expense:    
Operating costs and expenses excluding non-cash share-based compensation 2,670,482 2,120,614
Total assets:    
Total Assets 2,872,341 2,157,359
Operating Segments [Member] | Patent Licensing [Member]    
Net loss:    
Net Loss (869,863) (1,249,305)
Operating costs and expenses excluding non-cash share-based compensation 1,066,016 1,953,520
Operating costs and expenses excluding non-cash share based compensation expense:    
Operating costs and expenses excluding non-cash share-based compensation 1,066,016 1,953,520
Total assets:    
Total Assets $ 499,568 $ 1,745,380